NVO stock slides as ZEUS heart trial misses key goal
NVO stock came under pressure after Novo Nordisk said its ZEUS phase 3 trial of ziltivekimab failed to cut major adverse cardiovascular events versus placebo in people with ASCVD, CKD and inflammation, despite lowering IL-6 pathway markers. Bloomberg called it a blow to growth beyond obesity and diabetes; the company still expects no change to its 2026 profit outlook.
Key Takeaways
- Ziltivekimab hit its IL-6 biological targets but did not reduce MACE risk versus placebo (hazard ratio 0.99; 95% CI 0.88–1.11).
- ZEUS enrolled over 6,300 people with ASCVD, CKD, and inflammation (hsCRP ≥2 mg/L), testing once-monthly 15 mg shots.
- Adverse-event rates were broadly similar to placebo, though serious infections were more common with the drug.
- HERMES and ARTEMIS heart studies continue, with readouts expected in the first half of 2027.
- The miss triggers a non-cash impairment in Q3 2026 but leaves Novo’s 2026 adjusted operating profit outlook unchanged.
On 31 July 2026, Novo Nordisk released headline results from ZEUS, a late-stage cardiovascular outcomes trial of investigational antibody ziltivekimab. The update quickly became a market story for True Crime & Unsolved Mysteries readers tracking how pipeline surprises move nvo stock and other large-cap biopharma names.
According to the company announcement carried by Yahoo Finance, the drug showed expected reductions in free IL-6 and high-sensitivity C-reactive protein. Those biological wins did not deliver fewer cardiovascular deaths, non-fatal heart attacks, or non-fatal strokes versus placebo.
What did the ZEUS phase 3 trial show?
ZEUS was a double-blind, placebo-controlled study in more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation marked by hsCRP of at least 2 mg/L. Patients received once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard care.
The primary MACE analysis produced a hazard ratio of 0.99 with a 95% confidence interval from 0.88 to 1.11—effectively no risk reduction. Bloomberg reported that analysts had widely expected at least some benefit, making the null result a setback for Novo’s push beyond obesity and diabetes.
“Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” said Martin Holst Lange, Novo’s chief scientific officer. He said the company remains committed to cardiovascular disease research despite the miss.
How does the ZEUS miss affect NVO stock and Novo’s outlook?
The Wall Street Journal reported that Novo Nordisk shares dropped after the candidate failed in the cardiovascular trial—pressure that helps explain why investors are focused on nvo stock today. Novo said the ZEUS outcome will not change its previously communicated adjusted operating profit outlook for 2026.
It will, however, lead to a non-cash impairment charge in the third quarter of 2026. Full ZEUS results are slated for an upcoming scientific meeting later this year.
What happens next for ziltivekimab after ZEUS?
Overall adverse events and serious adverse events were similar between ziltivekimab and placebo. Consistent with IL-6 inhibition, a higher share of patients on the drug had serious infections. There was no difference in all-cause mortality.
Two other outcomes trials—HERMES in heart failure and ARTEMIS after an acute heart attack—are planned to continue. Those readouts are anticipated in the first half of 2027, keeping ziltivekimab in play even after ZEUS.
Ziltivekimab is a fully human monoclonal antibody targeting the IL-6 ligand. Novo is developing it for cardiovascular disease, acute myocardial infarction, and heart failure with preserved ejection fraction. For U.S. investors, Novo’s ADRs trade on the New York Stock Exchange under the ticker NVO.